FindTrial
Sign In

Phase II clinical study of HP-3150 in patients with low back pain.

Phase II clinical study of HP-3150 in patients with low back pain.

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080222960
Enrollment
Unknown
Registered
2015-09-07
Start date
2015-09-07
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Low back pain

Interventions

investigational material(s) Generic name etc : HP-3150 INN of investigational material : Therapeutic category code : 264 Analgesics, anti-itchings, astrigents and anti-inflammatory agents Dosage and

Sponsors

Hisamitsu Pharmaceutical Co., Inc
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: -Patients in whom low back pain was diagnosed clinically

Exclusion criteria

Exclusion criteria: -Patients with abnormalities at the planned application site. -Patients with a serious hematologic disorder, hepatic dysfunction, renal dysfunction, hypertension, heart failure, or another complication that is clinically problematic. -Patients who have undergone a procedure that may affect assessment of pain, including surgery, nerve block, or percutaneous laser disc decompression, within six months before giving informed consent. -Patients with pain attributable to a complication whose low back pain cannot be assessed properly.

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026